Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Combination nicotine replacement therapy

PreclinicalSmall molecule

SState University of New York at Buffalo

2

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Remote Vs. in-PersonActive, not recruiting

Smokeless TobaccoUnknown status

Remote Vs. in-PersonPreclinical

Active, not recruiting

Smokeless TobaccoPreclinical

Unknown status

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Remote Vs. in-Person

NCT06822049

Clinical

Trials by Indication[1]

Tobacco1 trial

UW Withdraw From Tobacco Study

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT04969198·232 enrolled

Smokeless Tobacco1 trial

Treating Smokeless Tobacco Use in Rural Veterans

Unknown status·MMark Vander Weg·N/A·NCT02994082·123 enrolled

Remote vs. In-Person1 trial

Improving Efficiency, Quality, and Equity: Randomized Controlled Evaluations of Remote vs. In-Person Clinical Trial Methods; Remote vs. In-Person Study Evaluation (RISE) Trials

Active, not recruiting·SState University of New York at Buffalo·Preclinical·NCT06822049·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Combination nicotine replacement therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination nicotine replacement therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination nicotine replacement therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — State University of New York at Buffalo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SState University of New York at Buffalo

Related News